Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada

BACKGROUND: Despite the use of statins, many patients with cardiovascular disease (CVD) have persistent residual risk. In a large Phase III trial (REDUCE-IT), icosapent ethyl (IPE) was shown to reduce the first occurrence of the primary composite endpoint of cardiovascular death, nonfatal myocardial...

Descripción completa

Detalles Bibliográficos
Autores principales: Lachaine, Jean, Charron, Jean-Nicolas, Gregoire, Jean C, Hegele, Robert A, Leiter, Lawrence A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124620/
https://www.ncbi.nlm.nih.gov/pubmed/37101608
http://dx.doi.org/10.2147/CEOR.S377935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124620/
https://www.ncbi.nlm.nih.gov/pubmed/37101608
http://dx.doi.org/10.2147/CEOR.S377935

Ejemplares similares